Literature DB >> 10776991

Prolactin secretion abnormalities in patients with the "syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex).

S B Raff1, J A Carney, D Krugman, J L Doppman, C A Stratakis.   

Abstract

Carney complex is a multiple neoplasia and lentiginosis syndrome. Acromegaly due to growth hormone (GH)-producing adenomas has been considered the only pituitary-related manifestation of the complex. In the present study, seven patients with Carney complex, who belonged to three unrelated kindreds and had relatives with acromegaly, were investigated for the presence of GH and prolactin (PRL) secretion abnormalities (familial cases). In addition, four patients with the complex and no family history of the complex were studied (sporadic cases). Seven of the patients were female and four were male; their mean age was 24.27 +/- 4.34 years. Sampling every 20 min for one hour in the morning and under fasting and unstimulated conditions was performed in all patients, for determination of serum PRL levels. Insulin-like growth factor-I (IGF-I) levels and magnetic resonance imaging (MRI) of the pituitary were also obtained. Patients who had elevated IGF-I levels underwent investigation for acromegaly by oral glucose tolerance test and thyrotropin-releasing hormone. Seven of the 11 patients (63.6%) had moderately high PRL levels (mean Z score value 2.12 +/- 0.66); three of these patients also had elevated IGF-I levels but a negative investigation for acromegaly. All patients had negative pituitary MRI. The patient with the highest PRL levels underwent 24-hour sampling every 20 min, which demonstrated a higher baseline secretion of this hormone with preservation of its circadian pulsatility. Hyperprolactinemia was present in two siblings and a parent-child pair. We conclude that prolactin hypersecretion, albeit mild, appears to be frequent in patients with Carney complex, is inherited in an autosomal dominant manner in kindreds with the syndrome, and may be associated with elevated IGF-I levels in some, but not all, patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10776991

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  14 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

2.  A novel splice site mutation of the PRKAR1A gene, C.440+5 G>C, in a Chinese family with Carney complex.

Authors:  J Fu; F Lai; Y Chen; X Wan; G Wei; Y Li; H Xiao; X Cao
Journal:  J Endocrinol Invest       Date:  2018-01-09       Impact factor: 4.256

3.  Astrocyte-elevated gene-1 mediates insulin-like growth factor 1-induced the progression of cardiac myxoma.

Authors:  Changcun Fang; Yuwen Shen; Peng Qi; Zhengqin Liu; Min Zhang; Xinyan Pang
Journal:  Tumour Biol       Date:  2015-07-10

4.  Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing.

Authors:  Paraskevi Salpea; Anelia Horvath; Edra London; Fabio R Faucz; Annalisa Vetro; Isaac Levy; Evgenia Gourgari; Andrew Dauber; Ingrid A Holm; Patrick J Morrison; Margaret F Keil; Charalampos Lyssikatos; Eric D Smith; Marc A Sanidad; JoAnn C Kelly; Zunyan Dai; Philip Mowrey; Antonella Forlino; Orsetta Zuffardi; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

Review 5.  Clinical genetics of multiple endocrine neoplasias, Carney complex and related syndromes.

Authors:  C A Stratakis
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

6.  Prkar1a haploinsufficiency ameliorates the growth hormone excess phenotype in Aip-deficient mice.

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Thomas Roetzer; Johannes A Hainfellner; Matthew F Starost; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

7.  Pituitary pathology in Carney complex patients.

Authors:  Sotirios G Stergiopoulos; Mones S Abu-Asab; Maria Tsokos; Constantine A Stratakis
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

8.  Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD.

Authors:  Lionel Groussin; Lawrence S Kirschner; Caroline Vincent-Dejean; Karine Perlemoine; Eric Jullian; Brigitte Delemer; Sabina Zacharieva; Duarte Pignatelli; J Aidan Carney; Jean Pierre Luton; Xavier Bertagna; Constantine A Stratakis; Jérôme Bertherat
Journal:  Am J Hum Genet       Date:  2002-11-06       Impact factor: 11.025

9.  Carney complex and other conditions associated with micronodular adrenal hyperplasias.

Authors:  Madson Q Almeida; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-12       Impact factor: 4.690

Review 10.  Pituitary pathology in patients with Carney Complex: growth-hormone producing hyperplasia or tumors and their association with other abnormalities.

Authors:  Sosipatros A Boikos; Constantine A Stratakis
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.